
Megan Neary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4770226/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prioritization of Antiâ€SARSâ€Covâ€2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2020, 108, 775-790.	4.7	118
2	The role of drug transporters in the kidney: lessons from tenofovir. Frontiers in Pharmacology, 2014, 5, 248.	3.5	62
3	Dose prediction for repurposing nitazoxanide in SARSâ€CoVâ€2 treatment or chemoprophylaxis. British Journal of Clinical Pharmacology, 2021, 87, 2078-2088.	2.4	46
4	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. Journal of Antimicrobial Chemotherapy, 2019, 74, 1670-1678.	3.0	42
5	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. Clinical Pharmacology and Therapeutics, 2017, 102, 529-536.	4.7	28
6	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Clinical Infectious Diseases, 2018, 67, 785-790.	5.8	25
7	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals. Clinical Infectious Diseases, 2019, 68, 446-452.	5.8	21
8	Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. Journal of Antimicrobial Chemotherapy, 2019, 74, 3281-3290.	3.0	15
9	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Journal of Antimicrobial Chemotherapy, 2019, 74, 3003-3010.	3.0	13
10	Scalable nanoprecipitation of niclosamide and <i>in vivo</i> demonstration of long-acting delivery after intramuscular injection. Nanoscale, 2021, 13, 6410-6416.	5.6	11
11	Pregnancy affects nevirapine pharmacokinetics. Pharmacogenetics and Genomics, 2016, 26, 381-389.	1.5	10
12	Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1169-1181.	3.3	8
13	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2020, 75, 1259-1266.	3.0	6
14	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. Open Forum Infectious Diseases, 2019, 6, ofz035.	0.9	5
15	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics, 2019, 20, 217-223.	1.3	4
16	Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. Journal of Antimicrobial Chemotherapy, 2020, 75, 1267-1271.	3.0	4
17	Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. Journal of Materials Chemistry B, 2022, 10, 4395-4404.	5.8	3
18	Pharmacokinetics of HIV therapies in pregnant patients: an update. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 449-461.	3.3	2